quinazolines has been researched along with Parotid Neoplasms in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cohen, PR; Jalalat, SZ | 1 |
Dahse, R; Kosmehl, H | 1 |
Chen, WT; Cheung, M; Choi, S; El-Naggar, AK; Jasser, SA; Mao, L; Myers, JN; Ryan, AJ; Sano, D; Zhao, M | 1 |
3 other study(ies) available for quinazolines and Parotid Neoplasms
Article | Year |
---|---|
Gefitinib-associated vitiligo: report in a man with parotid squamous cell carcinoma and review of drug-induced hypopigmentation.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Gefitinib; Humans; Male; Middle Aged; Parotid Neoplasms; Quinazolines; Vitiligo | 2013 |
Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma.
Topics: Aged; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; DNA, Neoplasm; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Parotid Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Adenoid Cystic; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Fluorescent Antibody Technique; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Parotid Neoplasms; Phosphorylation; Piperidines; Quinazolines; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2008 |